Entrectinib in NTRK fusion-positive, locally advanced or metastatic solid tumours and metastatic, ROS1-positive non-small cell lung cancer
Entrectinib has shown efficacy in the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase ( NTRK ) fusion-positive, locally advanced or metastatic solid tumours wh ...
read article